Deliver Your News to the World

Alligator Bioscience AB and Axis-Shield ASA moves successful project into next phase


Lund, December 1, 2006 -Alligator Bioscience, the protein optimization company, is pleased to announce that its collaboration with Axis-Shield ASA is now entering the next phase in the project.
In this collaboration, first announced in December 2002, Alligator has succeeded to further improve the properties of an antibody to be used in a vitamin B12 deficiency diagnostic test and the project is now moving into the phase of evaluating an adaptation of these antibodies to the diagnostic platform.
Vitamin B12 deficiency is an endemic disease, which can among other things cause the deterioration of the older persons’ memory and sometimes be mistaken for senility. The deficiency of this vitamin can also be found in other groups, for instance patients with stomach and intestine disease, HIV-positive, pregnant women as well as vegans. A simple test could facilitate diagnosing and a vitamin contribution could be set in for supplying the deficiency.
Axis-Shield has developed a test to measure the biologically active form of vitamin B12, which is currently limited to the use in research laboratories. The purpose of the collaboration with Alligator Bioscience is to improve and simplify the test so that it can be used in hospital laboratories and if possible in point of care.
Alligator Bioscience uses its proprietary FIND® technology to develop new and optimize existing therapeutic and diagnostic proteins.
Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers’ proteins and helping them to build more competitive pipelines. The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development.
Alligator Bioscience operates from the Ideon Science Park in Lund, and has 23 employees. The company has around 150 shareholders.
For further general information please visit


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.